GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight ...

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

Thrive Health Solutions also faces a lawsuit from drugmaker Eli Lilly, for allegedly making false claims about FDA approval ...

Semaglutide v. tirzepatide: What to know about popular weight loss and diabetes drugs like Ozempic. By Evan MacDonald, Staff writer April 27, 2024.

Source Reference: Rodriguez PJ, et al "Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity" JAMA Intern Med 2024; DOI: 10.1001/jamainternmed.2024.2525.